Señales en vivo de VYGR | Maximiza tus Ganancias con Getagraph.com

VENDER 119033 min ago

@ $7.28

Emitido: 14 feb 2024 @ 09:30

Retorno: 22.80%

Señal anterior: feb 13 - 09:30

Señal anterior: Comprar

Retorno: -1.38 %

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 16:00):

Stats
Volumen de hoy	544 472
Volumen promedio	669 490
Capitalización de mercado	485.45M
EPS	$0 ( 2024-02-28 )
Próxima fecha de ganancias	( $-0.440 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	3.01
ATR14	$0.00700 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Ferguson Toby	Buy	105 000	Common Stock
2024-04-02	Swartz Robin	Sell	1 357	Common Stock
2024-04-02	Sandrock Alfred	Sell	12 115	Common Stock
2024-03-25	Ferguson Toby	Buy	210 000	Stock Option (Right to Buy)
2024-03-25	Ferguson Toby	Buy	0

INSIDER POWER
44.71
Last 94 transactions
Buy: 7 546 876 \| Sell: 3 757 926

Volumen Correlación

Largo: 0.06 (neutral)

Corto: 0.43 (neutral)

Signal:(60.224) Neutral

Voyager Therapeutics Inc Correlación

10 Correlaciones Más Positivas
DYNT	0.929
DGLY	0.909
CRNC	0.909
ATNX	0.905
GFAI	0.905
LIVE	0.897
FTFT	0.896
ECOR	0.896
CFRX	0.889
APRE	0.886

10 Correlaciones Más Negativas
MTEX	-0.862
ZENV	-0.859
VERA	-0.852
GRIN	-0.848
GRPH	-0.843
DSPC	-0.835
JAN	-0.832
RIVN	-0.831
LAWS	-0.827
VERX	-0.826

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Voyager Therapeutics Inc Correlación - Moneda/Commodity

0.48
( neutral )

0.51
( weak )

0.00
( neutral )

0.56
( weak )

-0.48
( neutral )

Voyager Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$250.01M
Beneficio Bruto:	$245.57M (98.22 %)
EPS:	$3.08

FY	2023
Ingresos:	$250.01M
Beneficio Bruto:	$245.57M (98.22 %)
EPS:	$3.08

FY	2022
Ingresos:	$40.91M
Beneficio Bruto:	$34.72M (84.87 %)
EPS:	$-1.210

FY	2021
Ingresos:	$37.42M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.890

Financial Reports:

No articles found.

Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.